Host-derived plasminogen activator inhibitor-1 (PAI-1) concentration is critical for in vivo tumoral angiogenesis and growth

被引:129
作者
Bajou, K
Maillard, C
Jost, M
Lijnen, HR
Gils, A
Declerck, P
Carmeliet, P
Foidart, JM
Noel, A
机构
[1] Univ Liege, CRCE, Lab Tumor & Dev Biol, B-4000 Liege, Belgium
[2] Katholieke Univ Leuven, Fac Med, Ctr Mol & Vasc Biol, B-3000 Louvain, Belgium
[3] Katholieke Univ Leuven, Fac Pharmaceut Sci, Lab Pharmaceut Biol & Phytopharmacol, B-3000 Louvain, Belgium
[4] Katholieke Univ Leuven VIB, Ctr Transgene Technol & Gene Therapy, B-3000 Louvain, Belgium
关键词
PAI-1; cancer invasion; tumoral angiogenesis; serine protease; protease inhibitor;
D O I
10.1038/sj.onc.1207859
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Plasminogen activator inhibitor type 1 (PAI-1) plays a key role in tumor progression and is believed to control proteolytic activity and cell migration during angiogenesis. We report here that host PAI-1, at physiological concentration, promotes in vivo tumor invasion and angiogenesis. In sharp contrast, inhibition of tumor vascularization was observed when PAI-1 was produced at supraphysiologic levels, either by host cells (transgenic mice overexpressing PAI-1) or by tumor cells ( after transfection with murine PAI-1 cDNA). This study provides for the first time in vivo evidence for a dose-dependent effect of PAI-1 on tumor angiogenesis. Of great interest is the finding that PAI-1 produced by tumor cells, even at high concentration, did not overcome the absence of PAI-1 in the host, emphasizing the importance of the cellular source of PAI-1.
引用
收藏
页码:6986 / 6990
页数:5
相关论文
共 26 条
  • [11] Foekens JA, 2000, CANCER RES, V60, P636
  • [12] Gutierrez LS, 2000, CANCER RES, V60, P5839
  • [13] Isogai C, 2001, CANCER RES, V61, P5587
  • [14] Plasminogen activator inhibitor-1 represses integrin- and vitronectin-mediated cell migration independently of its function as an inhibitor of plasminogen activation
    Kjoller, L
    Kanse, SM
    Kirkegaard, T
    Rodenburg, KW
    Ronne, E
    Goodman, SL
    Preissner, KT
    Ossowski, L
    Andreasen, PA
    [J]. EXPERIMENTAL CELL RESEARCH, 1997, 232 (02) : 420 - 429
  • [15] Dose-dependent modulation of choroidal neovascularization by plasminogen activator inhibitor type 1:: Implications for clinical trials
    Lambert, V
    Munaut, C
    Carmeliet, P
    Gerard, RD
    Declerck, P
    Gils, A
    Claes, C
    Foidart, JM
    Noël, A
    Rakic, JM
    [J]. INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2003, 44 (06) : 2791 - 2797
  • [16] Influence of plasminogen activator inhibitor type 1 on choroidal neovascularization
    Lambert, V
    Munaut, C
    Noël, A
    Frankenne, F
    Bajou, K
    Gerard, R
    Carmeliet, P
    Defresne, MP
    Foidart, JM
    Rakic, JM
    [J]. FASEB JOURNAL, 2001, 15 (06) : 1021 - 1027
  • [17] Neointima formation and thrombosis after vascular injury in transgenic mice overexpressing plasminogen activator inhibitor-1 (PAI-1)
    Lijnen, HR
    Van Hoef, B
    Umans, K
    Collen, D
    [J]. JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2004, 2 (01) : 16 - 22
  • [18] COEXPRESSION OF UROKINASE, UROKINASE RECEPTOR AND PAI-1 IS NECESSARY FOR OPTIMUM INVASIVENESS OF CULTURED LUNG-CANCER CELLS
    LIU, GH
    SHUMAN, MA
    COHEN, RL
    [J]. INTERNATIONAL JOURNAL OF CANCER, 1995, 60 (04) : 501 - 506
  • [19] Mouse aortic ring assay: A new approach of the molecular genetics of angiogenesis
    Masson V.
    Devy L.
    Grignet-Debrus C.
    Bernt S.
    Bajou K.
    Blacher S.
    Roland G.
    Chang Y.
    Fong T.
    Carmeliet P.
    Foidart J.-M.
    Noël A.
    [J]. Biological Procedures Online, 2002, 4 (1) : 24 - 31
  • [20] Plasminogen activator inhibitor-1 regulates tumor growth and angiogenesis
    McMahon, GA
    Petitclerc, E
    Stefansson, S
    Smith, E
    Wong, MKK
    Westrick, RJ
    Ginsburg, D
    Brooks, PC
    Lawrence, DA
    [J]. JOURNAL OF BIOLOGICAL CHEMISTRY, 2001, 276 (36) : 33964 - 33968